Anti Inflammatory News and Research

RSS

Hsp90 inhibitors may help fight cardiovascular disease, say researchers

New drugs that are helping fight a multi-front war on cancer may do the same for cardiovascular disease, Medical College of Georgia researchers said.

31 Mar 2010

Gene expression in breast tissue may help explain pregnancy-associated breast cancer

Expression of inflammatory-related genes in breast tissue of women who have previously given birth may explain the aggressiveness and frequency of pregnancy-associated breast cancer, according to new research at the University of Illinois at Chicago.

30 Mar 2010

Alcon acquires right to market DUREZOL ophthalmic corticosteroid in U.S.

Alcon, the world's leader in eye care, announced today that it received regulatory approval and finalized the acquisition of the rights in the United States for DUREZOL™ emulsion and the global rights, excluding Latin America, for ZYCLORIN™ from Sirion Therapeutics, Inc.

30 Mar 2010

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.

26 Mar 2010

Special medicated contact lenses can help treat common eye disorders

The popular dietary supplement vitamin E, loaded into special medicated contact lenses, can keep glaucoma medicine near the eye - where it can treat that common disease- almost 100 times longer than possible with current commercial lenses, scientists reported here today.

25 Mar 2010

Analgesics can decrease risk of breast or ovarian cancer

Postmenopausal women who regularly use aspirin and other analgesics (known as painkillers) have lower estrogen levels, which could contribute to a decreased risk of breast or ovarian cancer.

24 Mar 2010

Children with neurofibromatosis more likely to have cardiovascular problems

Researchers have discovered how a genetic disease known mainly for its life-threatening tumors also can cause sudden death from cardiovascular disease in children, and are mounting a clinical trial to develop treatments for the problem.

24 Mar 2010

Garnet BioTherapeutics commences treatment in GBT009 trial for incisional wounds following breast reconstruction surgery

Garnet BioTherapeutics, Inc., a regenerative medicine company focused on developing cell based therapies, today announced that the first patient has been treated in a Phase 2 multicenter, double-blind, placebo-controlled study of its lead product candidate GBT009 at Unity Hospital in Rochester, New York. GBT009 gives off a variety of pro-regenerative growth factors and cytokines which help repair damaged tissue and reduce inflammation, ultimately augmenting the body's ability to heal itself.

23 Mar 2010

EMA validates InterMune's pirfenidone MAA for IPF

InterMune, Inc. today announced that the company's Marketing Authorization Application (MAA), submitted on March 2 seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, was validated by the European Medicines Agency (EMA). Validation of the MAA by the EMA indicates that the application is complete and that the review process will begin on March 24. The proposed trade name for pirfenidone in both the United States and Europe is Esbriet®.

23 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

Cancer radiotherapy can increase risk of cardiovascular disease later in life

For an as yet unknown reason, cancer radiotherapy can increase the risk of cardiovascular disease later in life, a problem that is growing as more and more people survive their cancer diagnosis. New research from Karolinska Institutet now suggests that sustained inflammation induced by post-radiotherapy changes in the gene expression in the arteries could be the cause.

22 Mar 2010

Effective defense against HIV: Acne drug minocycline

Johns Hopkins scientists have found that a safe and inexpensive antibiotic in use since the 1970s for treating acne effectively targets infected immune cells in which HIV, the virus that causes AIDS, lies dormant and prevents them from reactivating and replicating.

20 Mar 2010

Acne drug prevents HIV breakout

18 Mar 2010

Findings from Study 305 evaluating the effect of Northera reported

Chelsea Therapeutics International, Ltd. reported findings from Study 305, a study evaluating the effect of Northera™ (Droxidopa), an investigational agent being studied for the treatment of neurogenic orthostatic hypotension (NOH), on patients' 24-hour blood pressure (BP) profile.

18 Mar 2010

New specialty service at Montefiore Medical Center helps patients with drug allergies

A Westchester patient takes aspirin for pain, but develops rashes and hives. A Bronx patient with a gastrointestinal problem caused by bacteria is prescribed penicillin, then passes out. A Bronx woman is given a contrast dye for an internal diagnostic exam, then her skin peels off.

18 Mar 2010

Blocking GM-CSF could reduce inflammation and deleterious effects of cigarette smoke exposure

Researchers in Australia have demonstrated that blocking a certain protein can reduce or prevent cigarette smoke-induced lung inflammation in mice. Inflammation underlies the disease process of chronic obstructive pulmonary disease (COPD) and many other smoking-related ailments.

18 Mar 2010

Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002

Zogenix, Inc., a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen. ZX002 is being developed for the treatment of moderate to severe pain in individuals who require around-the-clock opioid therapy for the control of pain.

17 Mar 2010

Acetaminophen safe and effective for reducing postpartum pain

For many mothers of newborns, lingering pain from the delivery can interfere with their first days with their infant. A recent review examined whether over-the-counter medications containing acetaminophen - Tylenol for example − provided adequate relief for such pain and concluded that they are effective.

17 Mar 2010

Quinnova Pharmaceuticals introduces NEOSALUS CREAM for chronic inflammatory skin conditions

Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets novel topical delivery platform-based prescription drugs, announced the launch of its NEOSALUSTM CREAM. NEOSALUS CREAM, the latest addition to Quinnova’s NEOSALUS brand, is a prescription product with anti-inflammatory properties that can be used without age or long-term use restrictions for the treatment of a variety of chronic inflammatory skin conditions like atopic dermatitis, contact dermatitis, and hand eczema.

16 Mar 2010

Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis

Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.

16 Mar 2010

Anti Inflammatory News and Research

Hsp90 inhibitors may help fight cardiovascular disease, say researchers

Gene expression in breast tissue may help explain pregnancy-associated breast cancer

Alcon acquires right to market DUREZOL ophthalmic corticosteroid in U.S.

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

Special medicated contact lenses can help treat common eye disorders

Analgesics can decrease risk of breast or ovarian cancer

Children with neurofibromatosis more likely to have cardiovascular problems

Garnet BioTherapeutics commences treatment in GBT009 trial for incisional wounds following breast reconstruction surgery

EMA validates InterMune's pirfenidone MAA for IPF

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Cancer radiotherapy can increase risk of cardiovascular disease later in life

Effective defense against HIV: Acne drug minocycline

Acne drug prevents HIV breakout

Findings from Study 305 evaluating the effect of Northera reported

New specialty service at Montefiore Medical Center helps patients with drug allergies

Blocking GM-CSF could reduce inflammation and deleterious effects of cigarette smoke exposure

Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002

Acetaminophen safe and effective for reducing postpartum pain

Quinnova Pharmaceuticals introduces NEOSALUS CREAM for chronic inflammatory skin conditions

Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News